BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioInvest

Samsung Biologics Reports KRW 1.49 Trillion Q3 Revenue as Global Manufacturing Expansion Drives Growth

Recorded Q3'26 revenue of KRW 1,490 billion and operating profit of KRW 640 billion Plant 5 ramp-up and U.S. manufacturing operations contribute to earn...

October 23, 2026 | Company results

ESTEVE CDMO Invests Over $80 Million to Expand Pharmaceutical Manufacturing Capabilities in China

After more than two decades in China, ESTEVE CDMO marks a new chapter in its commitment to the country and the region. With more than $...

October 23, 2026 | News

Continuity Biosciences Secures $9.6M Gates Foundation Grant to Advance Multi-Year HIV Prevention Implant

Funding supports development of a subcutaneous implant designed to deliver HIV prevention medicine for multiple years from a single placement, advancing to...

October 16, 2026 | News

12 Biotechs in Hong Kong's 18A Queue, and What Each Says It Will Spend the Money On

Every Hong Kong biotech applicant has to tell investors what it will do with the money it raises. On the evidence of the twelve 18A application proofs that...

October 07, 2026 | Analysis

CSL, Alentis Forge $1.55B Partnership to Advance Lixudebart for Kidney and Liver Diseases

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared CSL and Alentis Therapeuti...

October 06, 2026 | News

Novartis Signs $7.8B RNA Therapeutics Deal With Abogen Biosciences

Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other...

October 05, 2026 | News

Piramal Pharma Invests $5.3M to Expand Drug Substance Manufacturing in Canada

Piramal Pharma Solutions is investing over $5.3 million in its Aurora drug substance facility to upgrade site infrastructure. With its investment throug...

October 01, 2026 | Analysis

Novartis Inks Up to $900M Global Licensing Deal with BoomRay for Radioligand Therapy Asset

Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision onco...

September 23, 2026 | News

Novo Holdings Makes Strategic Investment in China’s Wound Care CDMO ForYou Medical

Novo Holdings, a leading global healthcare and life sciences investor, announced a strategic minority investment in Huizhou ForYou Medical Devices Co., Ltd...

September 14, 2026 | News

CordenPharma Invests €80M to Expand Sterile Injectable Manufacturing Capacity in Italy

CordenPharma accelerates sterile injectable CDMO manufacturing expansion with €80 million multi-year investment in new facility and additional as...

September 11, 2026 | News

Solstice Oncology Launches with $225M Series A to Advance Harbour BioMed’s Porustobart

Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning...

September 11, 2026 | News

South Korea’s Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech in $2.3B Deal

HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including ob...

August 25, 2026 | News

Ommo Technologies Raises Series A to Scale Spatial Intelligence Platform for Physical AI

VMS Group, a global alternative investment specialist, announced that its portfolio company, Ommo Technologies (Ommo), a spatial intelligence tec...

August 13, 2026 | News

Aureka Biotechnologies Raises $100M Series B to Advance AI-Driven Drug Discovery

Aureka Biotechnologies announced the close of a US$100 million Series B financing on Aug. 10, 2026. Granite Asia funded the first tranche exclusively, and ...

August 12, 2026 | News

Stay Connected